retroviral construct administered by peripheral intravenous infusion Phase 1 trial of FVIII gene transfer for severe hemophilia A using a

doi:10.1182/blood-2003-01-0167Prepublished online May 22, 2003;2003 102: 2038-2045€€€€Jolly and Deborah HurstTom E. Moon, Veronica Cole, Sandhya Ramanathan-Girish, Holger Roehl, Nancy Sajjadi, Douglas J. Jerry S. Powell, Margaret V. Ragni, Gilbert C. White II, Jeanne M. Lusher, Carol Hillman-Wiseman,€

[1]  E. Check.  Second cancer case halts gene-therapy trials , 2003, Nature.

[2]  Christof von Kalle,et al.  A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. , 2003, The New England journal of medicine.

[3]  A. Batorova,et al.  Continuous infusion of coagulation factors , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  M. Gore,et al.  Purified herpes simplex virus thymidine kinase retroviral particles: , 2002, Cancer Gene Therapy.

[5]  J. Nemunaitis,et al.  Toxicity assessment of intratumoral injection of the herpes simplex type I thymidine kinase gene delivered by retrovirus in patients with refractory cancer. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  G. White,et al.  Gene Therapy in Hemophilia: Clinical Trials Update , 2001, Thrombosis and Haemostasis.

[7]  E G Tuddenham,et al.  The hemophilias--from royal genes to gene therapy. , 2001, The New England journal of medicine.

[8]  D. Treco,et al.  Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. , 2001, The New England journal of medicine.

[9]  D. Jolly,et al.  Factors affecting long-term expression of a secreted transgene product after intravenous administration of a retroviral vector. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  M. Ragni.  New‐generation recombinant factor concentrates: bridge to gene therapy , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  K. High.  Gene therapy: a 2001 perspective , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[12]  T. VandenDriessche,et al.  Gene therapy for hemophilia , 2001, The journal of gene medicine.

[13]  K. Boekelheide,et al.  Analysis of testes and semen from rabbits treated by intravenous injection with a retroviral vector encoding the human factor VIII gene: no evidence of germ line transduction. , 2000, Human gene therapy.

[14]  D. Lillicrap.  Hemophilia treatment. Gene therapy, factor VIII antibodies and immune tolerance: hopes and concerns. , 2000, Haematologica.

[15]  J. Nemunaitis,et al.  Long-term follow-up of retroviral vector-administered interferon-γ (IFN-γ) gene in metastatic melanoma , 2000, Cancer Gene Therapy.

[16]  A. Batorova,et al.  Intermittent injections vs. continuous infusion of Factor VIII in haemophilia patients undergoing major surgery , 2000, British journal of haematology.

[17]  S. Chang,et al.  Generation of retroviral packaging and producer cell lines for large-scale vector production and clinical application: improved safety and high titer. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  Thompson.  Gene therapy for the haemophilias , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  T. VandenDriessche,et al.  Long-term persistence of human bone marrow stromal cells transduced with factor VIII-retroviral vectors and transient production of therapeutic levels of human factor VIII in nonmyeloablated immunodeficient mice. , 2000, Human gene therapy.

[20]  Alan McClelland,et al.  Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector , 2000, Nature Genetics.

[21]  J. Lusher.  Gene therapy for hemophilia A and B: patient selection and follow-up, requirements for a cure. , 1999, Thrombosis and haemostasis.

[22]  T. Dubensky,et al.  The Resistance of Retroviral Vectors Produced from Human Cells to Serum Inactivation In Vivo and In Vitro Is Primate Species Dependent , 1999, Journal of Virology.

[23]  D. Jolly,et al.  Animal Testing of Retroviral-Mediated Gene Therapy for Factor VIII Deficiency , 1999, Thrombosis and Haemostasis.

[24]  S. Cai,et al.  Intramuscular injection of an adenoviral vector expressing hepatocyte growth factor facilitates hepatic transduction with a retroviral vector in mice. , 1999, Human gene therapy.

[25]  P. Briand,et al.  Amphotropic retroviral vectors displaying hepatocyte growth factor-envelope fusion proteins improve transduction efficiency of primary hepatocytes. , 1998, Human gene therapy.

[26]  C. Kessler,et al.  In vivo recovery with products of very high purity — assay discrepancies , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[27]  D. Jolly,et al.  Human immunodeficiency virus immunotherapy using a retroviral vector. , 1998, Current topics in microbiology and immunology.

[28]  E. Berntorp.  Second Generation, B-Domain Deleted Recombinant Factor VIII , 1997, Thrombosis and Haemostasis.

[29]  K. Pasi.  Gene therapy for haemophilia , 2001, Bailliere's clinical haematology.

[30]  M. van den Berg,et al.  The Nijmegen Modification of the Bethesda Assay for Factor VIII:C Inhibitors: Improved Specificity and Reliability , 1995, Thrombosis and Haemostasis.

[31]  M. Manco‐Johnson,et al.  Results of secondary prophylaxis in children with severe hemophilia , 1994, American journal of hematology.

[32]  H. Pettersson,et al.  Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B , 1992, Journal of internal medicine.

[33]  T. Palmer,et al.  Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[34]  A. Miller,et al.  Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection , 1990, Molecular and cellular biology.

[35]  E. Wenzel,et al.  Measurement of factor VIII procoagulant antigen in normal subjects and in hemophilia A patients by an immunoradiometric assay and by an enzyme-linked immunosorbent assay. , 1987, Haemostasis.

[36]  M. Blombäck,et al.  Clinical Application of a Chromogenic Substrate Method for Determination of Factor VIII Activity , 1985, Thrombosis and Haemostasis.

[37]  D. Green,et al.  Proceedings: A more uniform measurement of factor VIII inhibitors. , 1975, Thrombosis et diathesis haemorrhagica.